Overview AZD2066 Cocktail Study Status: Completed Trial end date: 2009-09-01 Target enrollment: Participant gender: Summary The aims of this study are to examine the effect of repeated doses of AZD2066 and of caffeine, bupropion, tolbutamide, omeprazole, metoprolol and midazolam on the blood concentrations of each other Phase: Phase 1 Details Lead Sponsor: AstraZenecaTreatments: BupropionCaffeineMetoprololMidazolamOmeprazoleTolbutamide